PMC:7283670 / 11738-12015 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T53","span":{"begin":190,"end":198},"obj":"Disease"},{"id":"T54","span":{"begin":210,"end":219},"obj":"Disease"}],"attributes":[{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased exten"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T83473","span":{"begin":136,"end":137},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased exten"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T23770","span":{"begin":0,"end":9},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased exten"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":210,"end":219},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased exten"}

{"project":"LitCovid-PubTator","denotations":[{"id":"221","span":{"begin":190,"end":198},"obj":"Disease"},{"id":"222","span":{"begin":210,"end":219},"obj":"Disease"}],"attributes":[{"id":"A221","pred":"tao:has_database_id","subj":"221","obj":"MESH:C000657245"},{"id":"A222","pred":"tao:has_database_id","subj":"222","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased exten"}